[Discrepancy between the clinical and immunologic picture of in vitro diagnosis during transfer factor therapy in a patient with Wiscott-Aldrich syndrome].
The attempt of an interval treatment in a patient affected with Wiscott-Aldrich syndrome with transfer factor between the 6th and 14th month of life had good clinical success initially which coincided with the normalization of in vitro stimulation of the patient's lymphocytes. Only short-term (in vitro) measurable effects could be achieved by the transfer factor. Whereas clinical therapy effects were diminishing from treatment phase to treatment phase, it was possible to observe further positive results in paraclinical findings. It was only MLC reactivity that correlated with the clinical picture. Etiologically, all findings gained speak in favour of a helper cell defect and/or monocyte defect. TF therapy was not repeated because of the findings obtained and the clinical course.
D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008297:Male; D014165:Transfer Factor / Q000494:pharmacology / Q000627:therapeutic use*; D014923:Wiskott-Aldrich Syndrome / Q000097:blood / Q000175:diagnosis / Q000276:immunology
D014165:Transfer Factor
Uber Diskrepanzen zwischen klinischem Bild und immunologischer in vitro-Diagnostik unter Transfer-Faktor-Therapie bei einem Patienten mit Wiskott-Aldrich-Syndrom.